Wells Fargo’s Eterna Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Hold
0
-$67 7059
2024
Q1
Hold
0
6754
2023
Q4
Hold
0
6931
2023
Q3
Hold
0
6889
2023
Q2
Hold
0
6940
2023
Q1
Hold
0
7092
2022
Q4
Hold
0
6839
2022
Q3
Hold
0
6828
2022
Q2
Sell
-7
Closed -$50.2K 6974
2022
Q1
$101K Sell
7
-1
-13% -$19K ﹤0.01% 5325
2021
Q4
$238K Buy
8
+4
+100% +$218K ﹤0.01% 5172
2021
Q3
$261K Buy
+4
New +$345K ﹤0.01% 4990
2021
Q2
Hold
0
6394
2021
Q1
Hold
0
6985
2020
Q4
Hold
0
6598
2020
Q3
Hold
0
6458
2020
Q2
Hold
0
6402
2020
Q1
Hold
0
6337
2019
Q4
Hold
0
6439
2019
Q3
Hold
0
6451
2019
Q2
Hold
0
6409
2019
Q1
Hold
0
6146
2018
Q4
Hold
0
6449
2018
Q3
Hold
0
6439
2018
Q2
Hold
0
6380
2018
Q1
Hold
0
6422
2017
Q4
Hold
0
6392
2017
Q3
Hold
0
6344
2017
Q2
Hold
0
6275
2017
Q1
Hold
0
6351
2016
Q4
Hold
0
6306
2016
Q3
Hold
0
6212
2016
Q2
Hold
0
6153
2016
Q1
Hold
0
6257
2015
Q4
Hold
0
6269
2015
Q3
Hold
0
6259
2015
Q2
Hold
0
6388
2015
Q1
Hold
0
6217
2014
Q4
Hold
0
6258
2014
Q3
Hold
0
6211
2014
Q2
Hold
0
6149
2014
Q1
Hold
0
5923
2013
Q4
Hold
0
5778
2013
Q3
Hold
0
5692
2013
Q2
Hold
0
5603

Other funds holding ERNA

Wells Fargo's ERNA Position: Q2 2024 in Review

Wells Fargo held its Eterna Therapeutics (ERNA) position steady in Q2 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7059.

Wells Fargo first reported a position in ERNA in Q3 2021 and has held it in 3 quarters since. The position peaked at $261K in Q3 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q2 2024.

  • Wells Fargo held 0 shares of Eterna Therapeutics worth $0 as of Q2 2024.
  • Wells Fargo left its Eterna Therapeutics share count unchanged in Q2 2024.
  • Eterna Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2024, its #7059 holding.
  • Wells Fargo first reported a position in Eterna Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Wells Fargo's Eterna Therapeutics position peaked at $261K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.